Viewing StudyNCT03409081



Ignite Creation Date: 2024-05-06 @ 11:00 AM
Last Modification Date: 2024-10-26 @ 12:38 PM
Study NCT ID: NCT03409081
Status: NO_LONGER_AVAILABLE
Last Update Posted: 2018-09-13
First Post: 2018-01-18

Brief Title: Early Access Program EAP of Gilteritinib ASP2215 in Patients With FMS-like Tyrosine Kinase 3 FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia AML or With FLT3-Mutated AML in Complete Remission CR With Minimal Residual Disease MRD
Sponsor: Astellas Pharma Global Development Inc
Organization: Astellas Pharma Inc

Organization Data

Organization: Astellas Pharma Inc
Class: INDUSTRY
Study ID: 2215-CL-9200
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor: Astellas Pharma Global Development Inc
Lead Sponsor Class: INDUSTRY
Responsible Party: None
Responsible Party Title: None
Responsible Party Type: SPONSOR
Responsible Party Affiliation: None
Old Name: None
Old Organization: None

Collaborators